MycRx is developing oral small molecule inhibitors that specifically target the Myc oncoprotein, a critical driver of cancer progression found in over 1 million new patients annually. The company's proprietary structural biology approach has identified a unique, druggable site on Myc, positioning its compounds for effective transcriptional inhibition and significant anti-cancer activity.
Funding
Funding not disclosed
MRFounders
Product
Problem
The Myc oncoprotein is a key driver of cancer progression, affecting over one million new patients annually. Directly targeting Myc with small molecule inhibitors has been historically challenging due to its structural properties.
Solution
MycRx is developing oral small molecule inhibitors designed to specifically target the Myc oncoprotein. The company utilizes a proprietary structural biology approach to identify and exploit a unique, druggable site on Myc. This approach aims to achieve effective transcriptional inhibition, leading to significant anti-cancer activity. The goal is to develop safe and effective first-in-class treatments for cancer by directly inhibiting Myc.
Target Audience
The primary target audience includes cancer patients and healthcare providers seeking novel and effective treatments for cancers driven by Myc overexpression.
Features
- Oral small molecule inhibitors targeting the Myc oncoprotein
- Proprietary structural biology approach for identifying druggable sites on Myc
- Designed for effective transcriptional inhibition
- Potential for significant anti-cancer activity